intrexon

http://dna.com/

Last activity: 18.05.2024

Active

Categories: BioTechEnergyTechEngineeringFoodTechFutureGovTechHealthTechIndustryPlatformProductivity

Through the engineering of biology, Intrexon is helping to address some of the world’s most pressing challenges and is working with industry and government leaders to realize a better, healthier planet. Today our platform is delivering new therapies in health, supplying unique solutions to address global energy demand, developing unparalleled features and productivity advancements in food, creating innovative applications for consumers, and helping to restore and protect the environment.

To execute on its mission, Intrexon has integrated a suite of technologies and expertise across a number of cellular systems to drive development and commercialization of bio-based solutions. Our solutions include: Friendly™ Aedes mosquitoes genetically engineered to suppress the invasive Aedes aegypti mosquito; Arctic® apples that will not brown when bitten, sliced, or bruised; a clinically validated transcriptional gene switch to precisely control production of biotherapeutics; bovine reproductive technologies driving genetic gain for the dairy and beef industries; genetically engineered miniature swine models to provide better predictive efficacy in evaluation of new medicines; and our AquAdvantage® salmon bringing productivity benefits to the aquaculture industry through our majority-owned subsidiary AquaBounty. Intrexon’s cutting-edge platforms have broad applicability, thus opening the door to the considerable potential of engineered biology.

Intrexon and our collaborators are building solutions to challenging issues across fields as diverse as medicine, fuel, agriculture, nutrition, personal care, chemicals, and manufacturing, forging a sustainable path forward for current and future generations. We call our approach Better DNA® and invite you to discover more at www.dna.com or follow us on Twitter at @Intrexon, on Facebook and LinkedIn.

Twitter Email

Likes

1.28K

Followers

3.04K

Followers

9.55K

Mentions

Overview

Location

United States, Maryland, Germantown

Employees

501-1000

Phone

+1 540-961-0725

Founded date

1998

Mentions in press and media 27

Date	Title	Description
Sign up to see	Sign up to see	Sign up to see
Sep 27, 2019	How To Spot A Synthetic Biology Unicorn	Biotech is projected to reach $775 billion by 2024, but dozens of companies in the field of ... [+] synthetic biology are creating magical tools to go beyond that. Look here for the next unicorn. Jelena Trmčić for SynBioBeta
Apr 4, 2019	The Precision Indoor Plants Consortium Wants to Make Your Tomatoes Tasty Again	How often do you eat a tomato that’s as tasty as you remember them being in your childhood? Not often right? And when you do it’s likely an heirloom variety you’ve picked up at your local farmers’ market. That’s because the varieties of tom...
Mar 26, 2019	Animal AgTech, The Sector’s Awkward Uncle, Proudly Struts Its Stuff In San Fran	This year’s Rethink AgriFood Innovation Week in San Francisco saw an awkward uncle stride proudly into the week’s agenda for the first time with last Monday’s inaugural Animal AgTech Innovation Summit. Animal agritech often struggles to evi...
Sep 17, 2018	Here’s a look at Maryland’s publicly-traded biotech companies	When talk turns to Maryland’s biotech bonafides, the ideas and talent being produced by government institutions like NIH, and research-oriented universities with connected health systems such as Johns Hopkins and University of Maryland are ...
Jun 9, 2016	How Big Data is Disrupting Agriculture from Biological Discovery to Farming Practices	Editor’s Note: Vonnie Estes is an agtech consultant with a particular focus on building biotech-focused startups. She has worked in business development roles at three of the big 6 — Monsanto, Syngenta, and DuPont — and is a known face in t...
Jan 18, 2016	5 Lessons from Raising Venture Capital in Agtech	Editor’s Note: Matthew B. Crisp is president, CEO and co-founder of Benson Hill Biosystems, the ag solutions company that is improving plant genetics to increase crop productivity through photosynthesis. Benson Hill raised a $7.3 million Se...
Jan 13, 2016	JMP Group Announces Closing of $245M Harvest Intrexon Enterprise Fund	San Francisco, CA-based Harvest Capital Strategies has raised $245m for the Harvest Intrexon Enterprise Fund, an investment vehicle dedicated to funding companies that utilize the inventions, discoveries and technologies of Intrexon Corpora...
Dec 31, 2013	Rare disease biotech picks up $8M, drug development partner for DNA-based therapies	The goal for Agilis and Intrexon is to use Intrexon’s gene switch technology to develop drugs that will repair the defective gene and enable increased production of the frataxin protein. Under the options of the deal, Agilis and Intrexon co...
Dec 26, 2013	Intrexon acquires San Diego-based stem cell company for $26M	Germantown-based biotech company Intrexon Corp. has acquired a San Diego-based company for $26 million. According to CityBizList, the Maryland synthetic biology company bought Medistem Inc., which has led the development of “universal donor...
Sep 13, 2013	6 Big Time DC Fundings You Need to Know About	It's been a mild summer in the Capital, but for a few D.C. companies, it's been hot, with loads and loads of cash thrown their way. And while Labor Day unofficially counts as the end of the summer months, technically fall doesn't start unti...
Aug 7, 2013	Intrexon prepares to price $125M IPO [Startup Roundup]	Have news for the Startup Roundup? Get in touch.who’s getting funded? GlycoPure, Inc., based in Cambridge, has raised $700,000 in equity, according to SEC filings. The biotech company is modifying an existing method for converting the chemi...
Jul 22, 2013	VC firms invest $318M in MD companies [REPORT]	A new report from PricewaterhouseCoopers shows that $318 million was invested in early-stage Maryland companies between April and June, reports the Baltimore Sun. Those companies: Precision for Medicine, Inc., which offers services for medi...
Jul 19, 2013	What’s special about the 3 biotechs in the top 10 for Q2 venture investments?	But let’s look a little more closely at the those three biotechnology companies and what they say about what is drawing investor attention. Two of the three provide valuable services to other life science companies. The third has a heart fa...
May 22, 2013	Web dev shop SmartLogic searching for new office space [Startup Roundup]	This is the Startup Roundup. Every Wednesday morning, Technically Baltimore will put together the smaller pieces that make up our startup ecosystem. If you’ve got news to share, get in touch.who’s getting funded? Intrexon Corporation, based...
May 2, 2013	Intrexon Closes $150M Series F Financing	Intrexon Corporation, a Germantown, MD-based next generation synthetic biology company, closed a $150m Series F financing. Backers included Randal J. Kirk, Chairman and CEO of Intrexon, and Third Security, LLC, as well as new undisclosed ba...
Jan 13, 2012	Synthetic biology firm Intrexon starts $50M fundraising round	Privately held Intrexon, based in Blacksburg, Virginia, is a synthetic biology company developing ways to design and construct transgenes with unique characteristics not typically found in nature. Intrexon last year expanded its footprint i...
Oct 24, 2011	Human antibodies biotech firm Immunologix acquired by Intrexon	Immunologix’s mAbLogix technology platform was spun out of the Medical University of South Carolina. The company’s technology offers a safer, more reliable, less expensive and faster method of producing human antibodies. Current methods pro...
May 31, 2011	Synthetic biotech company Intrexon raises $100M	The money will be directed to Intrexon’s UltraVector platform, the company’s technology used to design and construct complex transgenes to achieve certain qualities that would not typically be found in nature. The engineering can result in ...
May 31, 2011	Intrexon Corporation Closes $100M Series E Financing	Intrexon Corporation, a synthetic biology company, has closed a $100m Series E financing round. Investors include new shareholders, who committed the majority portion of the round and existing backers, including Randal J Kirk, Intrexon’s Ch...
Feb 23, 2011	HIMSS: Where’s the imaging? (Morning Read)	Where’s the ‘smartest biotech investor’ putting his money? Ronald Kirk (and his $2.2 billion net worth) may be the “best biotech investor ever.” His next big thing? Intrexon, a secretive research-stage company that is working on the hot new...
	Human antibodies biotech firm Immunologix acquired by Intrexon	South Carolina biotechnology company Immunologix has been acquired by Virginia DNA technologies company Intrexon, which earlier this year raised $100 million in a series E round of fundraising. Charleston, South Carolina-based Immunologix h...
	Synthetic biology firm Intrexon starts $50M fundraising round	Biotechnology company Intrexon has launched a new fundraising round aimed at bringing in $50 million in new investment. The DNA technologies company has raised $17 million in equity financing in the effort so far, according to securities fi...
	Synthetic biotech company Intrexon raises $100M	Synthetic biotechnology company Intrexon — whose website is the descriptive www.dna.com — has raised $100 million that the company will use to expand its genetics technology. With the closing of its series E round of fundraising, Blacksburg...
	HIMSS: Where’s the imaging? (Morning Read)	Current medical news and unique business news for anyone who cares about the healthcare industry. Where’s the imaging at HIMSS 2011? The significance of digital radiology and cardiology, and the complex issues relating their “meaningful use...
	What’s special about the 3 biotechs in the top 10 for Q2 venture investments?	Cellular engineering, precision medicine, and using G protein-coupled receptors to treat heart failure and other conditions. That’s the focus of the three biotechnology companies that made the top 10 for venture investment deals last quarte...
	Rare disease biotech picks up $8M, drug development partner for DNA-based therapies	Amid somewhat of a renaissance in drug development for orphan diseases, another gene therapy company announced funding today for a potential treatment for a rare neurodegenerative condition called Friedreich’s ataxia (FRDA). Agilis Biothera...

Reviews 0

FAQ about intrexon

When was intrexon founded?

intrexon was founded in 1998.

What has the press written about intrexon?

Parsers VC has collected 27 articles mentioning intrexon, among them “How To Spot A Synthetic Biology Unicorn” (Sep 27, 2019) and “The Precision Indoor Plants Consortium Wants to Make Your Tomatoes Tasty Again” (Apr 4, 2019).

Is intrexon still active?

Yes, intrexon is active; its latest activity on Parsers VC dates from May 18, 2024.